Barricaid

Barricaid is a patented, bone-anchored spinal implant developed by Intrinsic Therapeutics, a medical device company based in Woburn, Massachusetts, United States. The device is designed to be implanted after a standard lumbar discectomy in patients who have large annular defects in the disc. Its purpose is to close the defect and reduce the risk of reherniation and the need for a second operation, addressing a long-standing problem in spine surgery. The Barricaid implant is positioned as the first device clinically proven to reduce the incidence of reherniation and reoperation in patients with large annular defects. According to the company, the implant anchors to healthy bone and allows the surgeon to preserve more of the disc. It is engineered to withstand roughly 330 pounds per square inch of pressure, which the company says is strong enough to support everyday activities. The technology originated with inventor Greg Lambrecht, whose firsthand experience with his mother's recurrent disc herniations inspired him to search for a better solution. Intrinsic Therapeutics then spent two decades working with surgeons, scientists, clinical investigators, and medical advisors to develop the Barricaid solution for patients at high risk of recurrence following discectomy. The company followed what it describes as a responsible and evidence-based introduction of new technology, studying Barricaid through multiple trials, including a multicenter level I randomized controlled trial that demonstrated superior outcomes to discectomy alone. This evidence led to FDA Pre-Market Approval in 2019. Barricaid is marketed to both physicians and patients. For physicians, the company emphasizes the clinical evidence showing reduced reherniation and reoperation. For patients, it highlights the potential to avoid repeat surgery and the associated debilitating pain, and it offers educational resources such as a candidate quiz. The brand's mission is to reduce needless suffering by ensuring Barricaid is accessible to patients and surgeons, with a vision of a world where lumbar herniation does not define lives. Intrinsic Therapeutics is the parent company and owner of the Barricaid brand. The company is headquartered in Woburn, Massachusetts, and the brand is primarily active in the United States market. Barricaid is a trademarked and patented technology.

The Barricaid implant began with inventor Greg Lambrecht, whose firsthand experience with his mother's recurrent disc herniations inspired him to search for a better solution. Intrinsic Therapeutics, the company behind the brand, then worked for two decades with world-renowned surgeons, scientists, clinical investigators, and medical advisors to develop the Barricaid solution for patients at high risk of recurrence following discectomy. Following the company's commitment to a responsible and evidence-based introduction of new technology, Barricaid was rigorously studied through multiple trials. These included a multicenter level I randomized controlled trial that demonstrated superior outcomes to discectomy alone. This clinical evidence led to FDA Pre-Market Approval in 2019. The device is designed to address a specific problem in spine surgery: after a discectomy, if the defect in the disc is larger than a standard pencil-top eraser, the chances of reherniation and a return to debilitating pain are significantly increased. Barricaid is implanted after the standard discectomy and anchors to healthy bone, allowing the surgeon to preserve more of the disc while reducing the risk of reherniation and reoperation. It is engineered to withstand 330 pounds per square inch of pressure. Intrinsic Therapeutics is headquartered in Woburn, Massachusetts, United States. The Barricaid brand is primarily marketed in the United States, targeting both physicians and patients. The company's mission is to reduce needless suffering by ensuring Barricaid is accessible to patients and surgeons, and its vision is a world where lumbar herniation doesn't define lives.

• 2019

  Barricaid received FDA Pre-Market Approval following a multicenter level I randomized controlled trial.

First device clinically proven to reduce reherniation and reoperation in patients with large annular defects after lumbar discectomy.

• Barricaid bone-anchored spinal implant

  A patented implant placed after lumbar discectomy to close large annular defects, anchor to healthy bone, and reduce reherniation and reoperation. Designed to withstand 330 psi.

1. 1Revolutionizing Herniated Disc Surgery | Barricaidbarricaid.com
2. 2For patients - Barricaidbarricaid.com
3. 3About us - Barricaidbarricaid.com
4. 4Barricaid (United States) - Wikidatawikidata.org